| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
91,540,000 |
| Market
Cap: |
34.79(M) |
| Last
Volume: |
1,296,467 |
Avg
Vol: |
1,292,882 |
| 52
Week Range: |
$0.38 - $0.9341 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Curis is a biotechnology company focused on the development of therapeutics for the treatment of cancer. Co.'s clinical stage drug candidates are: Emavusertib, which is being tested in a Phase 1/2 dose escalating clinical trial in patients with non-Hodgkin lymphomas; CI-8993, which is a monoclonal antibody; Fimepinostat, which is a small molecule that potently inhibits the activity of histone deacetylase, and phosphotidyl-inositol 3 kinase; CA-170, for which Co. has announced initial data from a clinical study in patients with mesothelioma in conjunction with the Society of lmmunotherapy of Cancer; and CA-327, which is a small molecule antagonist of PDL1 and TIM3.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Passeri Daniel R |
Director |
– • – |
2016-01-06 |
4 |
OE |
$1.57 |
$20,253 |
D/D |
12,900 |
211,798 |
|
- |
|
| Passeri Daniel R |
Director |
– • – |
2015-12-30 |
4 |
AS |
$3.01 |
$43,344 |
D/D |
(14,400) |
198,898 |
|
- |
|
| Passeri Daniel R |
Director |
– • – |
2015-12-30 |
4 |
OE |
$1.57 |
$22,608 |
D/D |
14,400 |
213,298 |
|
- |
|
| Passeri Daniel R |
Director |
– • – |
2015-12-29 |
4 |
AS |
$2.91 |
$32,592 |
D/D |
(11,200) |
198,898 |
|
- |
|
| Passeri Daniel R |
Director |
– • – |
2015-12-29 |
4 |
OE |
$1.57 |
$17,584 |
D/D |
11,200 |
210,098 |
|
- |
|
| Passeri Daniel R |
Director |
– • – |
2015-12-28 |
4 |
AS |
$2.84 |
$31,240 |
D/D |
(11,000) |
198,898 |
|
- |
|
| Passeri Daniel R |
Director |
– • – |
2015-12-28 |
4 |
OE |
$1.57 |
$17,270 |
D/D |
11,000 |
209,898 |
|
- |
|
| Passeri Daniel R |
Director |
– • – |
2015-12-24 |
4 |
AS |
$2.90 |
$7,540 |
D/D |
(2,600) |
198,898 |
|
- |
|
| Passeri Daniel R |
Director |
– • – |
2015-12-24 |
4 |
OE |
$1.57 |
$4,082 |
D/D |
2,600 |
201,498 |
|
- |
|
| Passeri Daniel R |
Director |
– • – |
2015-12-23 |
4 |
AS |
$2.90 |
$31,610 |
D/D |
(10,900) |
198,898 |
|
- |
|
| Passeri Daniel R |
Director |
– • – |
2015-12-23 |
4 |
OE |
$1.57 |
$17,113 |
D/D |
10,900 |
209,798 |
|
- |
|
| Passeri Daniel R |
Director |
– • – |
2015-12-22 |
4 |
AS |
$2.75 |
$104,500 |
D/D |
(38,000) |
198,898 |
|
- |
|
| Passeri Daniel R |
Director |
– • – |
2015-12-22 |
4 |
OE |
$1.57 |
$59,660 |
D/D |
38,000 |
236,898 |
|
- |
|
| Passeri Daniel R |
Director |
– • – |
2015-12-21 |
4 |
AS |
$2.87 |
$287,000 |
D/D |
(100,000) |
198,898 |
|
- |
|
| Passeri Daniel R |
Director |
– • – |
2015-12-21 |
4 |
OE |
$1.57 |
$157,000 |
D/D |
100,000 |
298,898 |
|
- |
|
| Passeri Daniel R |
Director |
– • – |
2015-12-18 |
4 |
AS |
$3.05 |
$576,450 |
D/D |
(189,000) |
198,898 |
|
- |
|
| Passeri Daniel R |
Director |
– • – |
2015-12-18 |
4 |
OE |
$1.57 |
$296,730 |
D/D |
189,000 |
387,898 |
|
- |
|
| Dr Reddys Laboratories Ltd |
10% Owner |
– – • |
2015-01-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
17,120,131 |
|
- |
|
| Fattaey Ali Ph.d. |
President & CEO |
• • – |
2014-08-27 |
4 |
B |
$1.60 |
$100,624 |
D/D |
62,890 |
65,890 |
2.81 |
- |
|
| Mcnab James R |
Director |
– • – |
2014-04-02 |
4 |
GD |
$0.00 |
$0 |
D/D |
30,000 |
1,049,688 |
|
- |
|
| Fattaey Ali Ph.d. |
President & COO |
• – – |
2013-12-11 |
4 |
B |
$2.52 |
$7,560 |
D/D |
3,000 |
3,000 |
2.74 |
- |
|
| Gray Michael |
CFO |
• – – |
2013-11-12 |
4 |
B |
$2.86 |
$28,600 |
D/D |
10,000 |
107,304 |
2.74 |
- |
|
| Pienta Kenneth |
Director |
– • – |
2013-11-08 |
4 |
B |
$2.95 |
$59,000 |
D/D |
20,000 |
30,000 |
2.39 |
- |
|
| Pienta Kenneth |
Director |
– • – |
2013-09-16 |
4 |
B |
$4.37 |
$43,691 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| Mcnab James R |
Director |
– • – |
2013-08-16 |
4 |
S |
$4.00 |
$200,000 |
I/I |
(50,000) |
50,000 |
|
- |
|
303 Records found
|
|
Page 3 of 13 |
|
|
